Day: December 23, 2020

Information about mandatory offer of share repurchase

Written by Customer Service on December 23, 2020. Posted in Public Companies.

Information about mandatory offer of share repurchaseJoint Stock Company “Grindeks” hereby informs that today according to 22nd December, 2020 Financial Capital Market Commission decision and the official announcement of the publisher “Latvijas Vestnesis” of December 23 rd, 2020, JSC “Grindeks” shareholder “Liplat Holding” Ltd. will begin the mandatory share repurchase offer process.The following details of this mandatory share repurchase offer (the “Offer”) are being published in accordance with section 73(4) of the Financial Instruments Market LAWAct (“FIML”):The TargetThe Target Company of the Mandatory Share Repurchase Offer: JSC “Grindeks”, registration number 40003034935; legal address: Riga, Krustpils Street 53, postal code: LV-1057, Latvia, T: +371 67083500, e-mail: grindeks@grindeks.lv, website: www.grindeks.lv.Offeror“Liplat...

Par obligāto akciju atpirkšanas piedāvājumu

Written by Customer Service on December 23, 2020. Posted in Public Companies.

Par obligāto akciju atpirkšanas piedāvājumuAkciju sabiedrība „Grindeks” informē, ka šodien, ievērojot Finanšu un kapitāla tirgus komisijas padomes 2020. gada 22. decembra lēmumu un atsaucoties uz 2020. gada 23. decembra paziņojumu oficiālajā izdevējā „Latvijas Vēstnesis”, sāksies AS „Grindeks” akcionāra SIA „Liplat Holding” izteiktais obligātais akciju atpirkšanas piedāvājums.Saskaņā ar Finanšu instrumentu tirgus likuma 73. panta ceturto daļu par obligāto akciju atpirkšanas piedāvājumu tiek publicēta šāda informācija:Informācija par piedāvājumuMērķa sabiedrība: AS „Grindeks”, vienotais reģistrācijas numurs 40003034935; juridiskā adrese: Rīga, Krustpils iela 53, LV-1057, Latvija, tālr.: +371 67083500, e-pasts: grindeks@grindeks.lv, interneta mājaslapa: www.grindeks.lv.PiedāvātājsSIA „Liplat Holding”, reģistrēta 11.04.2019 ar reģistrācijas...

Gaming and Leisure Properties, Inc. Announces Shareholder Election Results for Fourth Quarter Dividend

Written by Customer Service on December 23, 2020. Posted in Dividend Reports And Estimates.

WYOMISSING, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (“GLPI” or the “Company”) (NASDAQ: GLPI) announced today the results of shareholder elections relating to its quarterly dividend declared by its Board of Directors on November 5, 2020. The dividend of $0.60 per share of the Company’s common stock, par value $0.01 per share, consists of a combination of cash and shares and will be paid on December 24, 2020 to shareholders of record on November 16, 2020.Based on shareholder elections, the dividend will be paid in the form of approximately $27.6 million in cash and approximately 2.5 million shares of the Company’s common stock. The number of shares included for the common stock dividend election was calculated based on the volume weighted average of the trading prices of the Company’s common...

HSBC BANK PLC – Form 8.3 – Studio Retail Group plc

Written by Customer Service on December 23, 2020. Posted in Mergers And Acquisitions.

FORM 8.3

Euronet Worldwide, Inc., Acquires Bank of Ireland’s non-branch ATM fleet

Written by Customer Service on December 23, 2020. Posted in Mergers And Acquisitions.

LEAWOOD, Kan., Dec. 23, 2020 (GLOBE NEWSWIRE) — Euronet Worldwide, Inc. (NASDAQ: EEFT), a leading global electronic payments provider, has announced the acquisition of Bank of Ireland’s entire fleet of non-branch ATMs in the Republic of Ireland. Under terms of the agreement, Euronet will acquire 700 non-branch ATMs while the bank will still own and operate more than 750 ATMs located across its extensive branch network. The transfer of ownership to Euronet is planned for Feb 28, 2021. Euronet will assume full responsibility for managing the acquired ATM network and integrating it with the company’s existing ATM estate in the Republic of Ireland. In addition, Euronet plans additional investments to upgrade and enhance the ATMs with modern technology and new functionality to the benefit of consumers.No disruption in the operation...

Kvanto förvärvar 51 % av Mobileware Technology för att kombinera och utvidga sin digitala betalningsverksamhet i Indien

Written by Customer Service on December 23, 2020. Posted in Mergers And Acquisitions.

KÖPENHAMN, Danmark, Dec. 23, 2020 (GLOBE NEWSWIRE) — Kvanto Payment Services A/S (”Kvanto”) är glada över att tillkännage undertecknandet av ett avtal (”Avtalet”) med Mobileware Technology Pvt. Ltd. (”MWT”). Enligt villkoren i avtalet kommer Kvanto att äga 51 % av MWT i Indien för att fortsätta implementera Kvantos betalningsplattform i kombination med MWT:s befintliga betalningsteknik och kundbas. MWT kommer att representera och driva Kvanto framåt genom den exponentiellt växande marknaden för digital betalningshantering i Indien.Mobileware har implementerat digitala bankprodukter på ledande banker i Indien, inklusive Yes Bank och Kotak Mahindra Bank. Satsningen är baserad på Kvantos framgång med sin beprövade toppmoderna plattform och täckning som når över 400 banker över hela världen, och Mobilewares långvariga affärsrelationer...

Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update

Written by Customer Service on December 23, 2020. Posted in Earnings Releases And Operating Results.

All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completedPivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021MONMOUTH JUNCTION, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced its corporate highlights and financial results for its fiscal year ended September 30, 2020.Outlook Therapeutics also provided a clinical development and pre-commercialization update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic formulation of bevacizumab-vikg...

Acceptance and sale of FSRU LNG Croatia

Written by Customer Service on December 23, 2020. Posted in Public Companies.

Golar LNG Limited (“Golar”) announces today that the FSRU LNG Croatia (formerly known as the Golar Viking) has been accepted by its customer LNG Hrvatska d.o.o. (“LNG Hrvatska”), and that the sale of the FSRU has been completed. The sale will release approximately $47 million of free cash to Golar between Q4 2020 and Q1 2021 after repayment of the vessel debt facility and settlement of remaining conversion and commissioning costs. Golar will now operate and maintain the LNG Croatia for a minimum period of 10 years under contract to LNG Hrvatska.Forward-Looking StatementsThis press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Written by Customer Service on December 23, 2020. Posted in Public Companies.

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. The Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization.The Company’s clinical safety team has actively monitored the ongoing interim data of...

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Written by Customer Service on December 23, 2020. Posted in Public Companies.

FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately $24.5 million at a public offering price of $1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses.The shares of common stock in the public offering were offered pursuant to a registration statement on Form S-3 (File No. 333-244362), which was declared effective by the Securities and Exchange Commission (SEC) on August 20, 2020. The public offering was made only by means of a written prospectus...

Day: December 23, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals